NCT01229423已完成4 期
Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 62
- 主要终点
- Change From Baseline in Eyelash Length at Week 20
研究概览
简要总结
This study will evaluate the safety and efficacy of LATISSE® (bimatoprost 0.03%) in the augmentation of eyelashes in Korean women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Eyelash prominence assessment of minimal or moderate
- •Of Korean ethnicity
排除标准
- •Any eye disease or abnormality
- •Any ocular surgery or use of any eyelash extension or eyelash growth products within 3 months
- •Any permanent eyeliner within 5 years
- •Eyelash implants of any kind
- •Eyelash tint or dye application within 2 months
- •Use of any treatment that may affect hair growth within 6 months
研究组 & 干预措施
LATISSE®
Experimental
bimatoprost 0.03% (LATISSE®)
干预措施: bimatoprost 0.03% (Drug)
结局指标
主要结局
Change From Baseline in Eyelash Length at Week 20
时间窗: Baseline, Week 20
Change from baseline in eyelash length at Week 20. Measurements made were based on the mean length of the upper left and right eyelashes. A positive change from baseline indicates an increase in eyelash length, and a negative change from baseline indicates a decrease in eyelash length.
次要结局
- Percentage of Subjects With an Improvement in Satisfaction With Overall Eyelash Prominence at Week 20(Week 20)
- Percentage of Subjects Satisfied With Treatment at Week 20(Week 20)
- Change From Baseline in Eyelash Thickness at Week 20(Baseline, Week 20)
- Change From Baseline in Eyelash Intensity (Darkness) at Week 20(Baseline, Week 20)
- Percentage of Subjects With an Improvement of at Least 1-Point in Global Eyelash Assessment (GEA) Score at Week 20(Week 20)
研究者
相似试验
已完成
2 期
Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of GliomaGliomaAnaplastic AstrocytomaGlioblastoma MultiformeNCT00409214Light Sciences Oncology18
Unknown
4 期
Efficacy and Safety of LAIS® Mites Sublingual TabletsAllergic ConditionsNCT02277483Ajou University School of Medicine45
已完成
1 期
Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)Carcinoma, HepatocellularLiver NeoplasmsNCT00122876Light Sciences Oncology25
已完成
3 期
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)Type 2 DiabetesDiabetes MellitusNCT01485614Merck Sharp & Dohme LLC200
终止
1 期
Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AMLAcute Myeloid LeukemiaNCT00583102University of Iowa23